Purple Biotech Showcases Innovative Research at Cancer Conference
Purple Biotech Ltd., a forward-thinking clinical-stage company dedicated to developing advanced therapies, has secured a poster presentation at a prominent cancer research event. The American Association for Cancer Research (AACR) Special Conference on Advances in Pancreatic Cancer Research is a prestigious venue where groundbreaking oncological advancements are unveiled.
Details of the Presentation
The company’s poster presentation, titled “Exploratory biomarker evaluation of the randomized Phase 2 cohort of CM24 in combination with nivolumab and chemotherapy in advanced/metastatic pancreatic cancer,” is set to take place on Tuesday during the conference. This session, held in Boston, will showcase findings that underscore the potential advantages of CM24, a novel monoclonal antibody designed to enhance cancer treatment.
CM24's Role in Cancer Treatment
CM24 stands out due to its unique mechanism; it inhibits CEACAM1, a pathway that tumors exploit to escape the immune system. This antibody is designed to bolster the body’s natural defenses against cancer by specifically targeting the pathways that enable tumor survival. In conjunction with Bristol Myers Squibb's PD-1 inhibitor nivolumab, CM24 is being assessed against standard chemotherapy for patients with pancreatic ductal adenocarcinoma.
Progress and Future Directions
The ongoing Phase 2 study has garnered significant attention due to promising data that suggests improved survival rates and overall patient outcomes. Preliminary data presentations have indicated that the combination therapy results in better survival and response rates compared to chemotherapy alone. This data offers a hopeful perspective for patients participating in the trial.
Company Overview and Additional Projects
Purple Biotech is leading the charge in oncology innovation. In addition to CM24, the company is progressing with other projects like NT219 and IM1240. NT219 is an intriguing small molecule that targets specific protein pathways linked to tumor growth and has demonstrated anti-tumor activity in earlier trials. Meanwhile, IM1240 is designed to target a specific tumor-associated antigen to provoke a strong immune response.
Collaborations Enhancing Research Potential
The partnership with Bristol Myers Squibb has streamlined the clinical development of CM24, combining resources and expertise to effectively tackle the challenges of oncology therapeutics. Together, they aim to improve treatment protocols for patients facing difficult cancer diagnoses.
Conclusion: A Major Advancement for Oncology
Purple Biotech is dedicated to advancing innovation within the oncology sector. With CM24 showing encouraging results and a strong pipeline of projects, the company is setting new standards for the treatment of pancreatic cancer. The upcoming conference presentation will be a pivotal moment for the company, as they share their latest findings and engage with the scientific community to explore future opportunities.
Frequently Asked Questions
What is CM24?
CM24 is a humanized monoclonal antibody that inhibits CEACAM1, aiming to enhance immune responses against cancer cells, particularly in pancreatic cancer.
When will the AACR conference take place?
The AACR Special Conference on Advances in Pancreatic Cancer Research is scheduled for September 15 to 18, 2024.
What are the main findings presented about CM24?
The findings suggest that patients treated with CM24 alongside nivolumab and chemotherapy experience improved survival and response rates compared to those receiving standard chemotherapy.
How does Purple Biotech contribute to cancer research?
Purple Biotech develops first-in-class therapies aimed at overcoming tumor immune evasion and enhancing the effectiveness of current cancer treatments.
Who can be contacted for more information about Purple Biotech?
For additional information, you can contact Lior Fhima, Chief Financial Officer, at IR@purple-biotech.com.
